Description

The NFKBIA Knockout CAL-27 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human tongue squamous cell carcinoma line CAL-27, with targeted disruption of the NFKBIA gene (Homo sapiens). This stable loss-of-function model enables investigation of I??B?? functions in signal transduction and cancer biology. The gene editing was performed via CRISPR/Cas9-mediated genome modification, and the cell population is supplied for immediate culture and assay deployment.

The parental CAL-27 cell line, established from a tongue squamous cell carcinoma of a 56-year-old male, is an adherent epithelial model widely used in oral cancer research. It retains key signaling receptors such as TNFR, IL1R, and TLRs, providing a clinically relevant context to study inflammatory and survival pathways in head and neck cancer.

NFKBIA encodes I??B??, the primary cytoplasmic inhibitor of NF-??B transcription factors. I??B?? sequesters NF-??B dimers, predominantly p50/RELA (p65), in an inactive state. Pathway activation by TNF, IL-1, or LPS stimulates the IKK complex (IKK??, IKK??, IKK??) to phosphorylate I??B??, leading to its ??-TrCP-mediated ubiquitination and degradation. Liberated NF-??B dimers translocate to the nucleus and induce target genes such as CCND1, BCL2, BCL2L1, IL6, TNF, MMP9, and VEGFA. NFKBIA transcription is itself NF-??B-dependent, establishing an auto-regulatory loop. In the knockout, I??B?? absence results in constitutive nuclear NF-??B localization and persistent transcriptional activity, driving pro-survival and pro-inflammatory gene expression.

In CAL-27 oral cancer cells, NFKBIA knockout amplifies tumorigenic traits by sustaining NF-??B-mediated proliferation (via CCND1), apoptosis resistance (via BCL2 family members), and invasive signaling (via MMP9, VEGFA). This model recapitulates the hyperactive NF-??B state found in aggressive oral squamous cell carcinomas, thus facilitating studies of oncogenic signaling and therapeutic vulnerabilities.

Applications include mechanistic dissection of NF-??B pathway dynamics, drug screening for anti-inflammatory or anti-cancer agents, and functional analyses of tumor microenvironment interactions. Compatible assays encompass Western blotting for NFKBIA, phospho-p65, and IKK; RT-qPCR for target genes; NF-??B reporter assays; immunofluorescence for p65 translocation; flow cytometry for apoptosis/cell cycle; colony formation; transwell migration/invasion; and drug sensitivity profiling. For technical inquiries, contact Ascent Research.